1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Karo Pharma AB (publ)
  6. Summary
    KARO   SE0007464888

KARO PHARMA AB (PUBL)

(KARO)
  Report
Delayed Quote. Delayed Nasdaq Stockholm - 05/27 11:29:37 am
56.3 SEK   +1.08%
04/19Karo Pharma to Raise $262 Million in Rights Issue
MT
04/19Karo Pharma's rights issue fully subscribed
AQ
04/12Karo Pharma publishes the 2021 annual report
AQ
 SummaryQuotesChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
05/20/2022 05/23/2022 05/24/2022 05/25/2022 05/27/2022 Date
56.4(c) 56.1(c) 55.7(c) 55.7(c) 56.3(c) Last
34 432 69 046 81 025 51 995 61 651 Volume
+0.36% -0.53% -0.71% 0.00% +1.08% Change
More quotes
Estimated financial data (e)
More Financials
Company
Karo Pharma AB, formerly known as Karo Bio AB, is a Sweden-based biopharmaceutical company engaged in the research and development of drugs based on the nuclear receptors. The Company’s pipeline comprises three projects: Estrogen Receptor Beta (ERbeta) cancer, a platform, which focuses on the development of ERbeta in cancer treatment; ERbeta multiple sclerosis (MS), which specializes in the autoimmune disease MS... 
Sector
Pharmaceuticals
Calendar
07/20Earnings Release
More about the company
All news about KARO PHARMA AB (PUBL)
04/19Karo Pharma to Raise $262 Million in Rights Issue
MT
04/19Karo Pharma's rights issue fully subscribed
AQ
04/12Karo Pharma publishes the 2021 annual report
AQ
04/04Karo Pharma completes the acquisition of the E45 brand from Reckitt
AQ
04/01Reckitt Completes Sale of E45 Brand to Karo Pharma
MT
04/01Karo Pharma completes the acquisition of the E45® brand from Reckitt
AQ
03/28KARO PHARMA AB (OM : KARO) acquired Del Decus Enterprises Ltd.
CI
03/24KARO PHARMA AB(OM : KARO) dropped from OMX Nordic All-Share Index
CI
03/23Karo Pharma publishes prospectus relating to the rights issue and receives approval to ..
AQ
03/23Karo Pharma Receives Approvals For $265 Million Rights Issue, Change Of Listing To Nasd..
MT
03/22KARO PHARMA AB (PUBL) : RIGHTS ISSUE: 3 new shares @ 52 SEK for 14 existing shares
FA
03/16Karo Pharma To Initiate $262 Million Rights Issue To Repay Bridge Loan
MT
03/16Karo Pharma resolves on a fully guaranteed rights issue of approximately SEK 2.5 billio..
AQ
03/10Nasdaq Stockholm Approves Delisting Application From Karo Pharma
MT
03/10Karo Pharma receives approval to delist the Company's share from Nasdaq Stockholm in co..
AQ
More news
News in other languages on KARO PHARMA AB (PUBL)
04/19Karo Pharma lève 262 millions de dollars dans le cadre d'une émission d'actions.
04/01Reckitt conclut la vente de la marque E45 à Karo Pharma
03/28KARO PHARMA AB (PUBL) (OM : KARO) a acquis Del Decus Enterprises Ltd.
03/23Karo Pharma reçoit les approbations pour une émission de droits de 265 millions de doll..
03/10Nasdaq Stockholm approuve la demande de radiation de Karo Pharma
More news
Chart KARO PHARMA AB (PUBL)
Duration : Period :
Karo Pharma AB (publ) Technical Analysis Chart | KARO | SE0007464888 | MarketScreener
Technical analysis trends KARO PHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Managers and Directors
Christoffer Lorenzen Chief Executive Officer
Jon Johnsson Chief Financial Officer
Bo Jesper Hansen Chairman
Sofia Pedersen Vice President-Scientific Affairs
Håkan Åström Independent Director
Sector and Competitors
1st jan.Capi. (M$)
KARO PHARMA AB (PUBL)-5.64%1 564
JOHNSON & JOHNSON5.86%476 521
PFIZER, INC.-8.70%302 483
ELI LILLY AND COMPANY17.11%291 184
ROCHE HOLDING AG-13.00%281 098
ABBVIE INC.10.78%265 067